Compare IDAI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDAI | LSTA |
|---|---|---|
| Founded | 2016 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 20.9M |
| IPO Year | N/A | N/A |
| Metric | IDAI | LSTA |
|---|---|---|
| Price | $3.69 | $2.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 158.6K | 23.8K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,727,824.00 | $1,070,000.00 |
| Revenue This Year | $3.46 | N/A |
| Revenue Next Year | $219.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 72.57 | N/A |
| 52 Week Low | $1.43 | $1.81 |
| 52 Week High | $18.75 | $4.20 |
| Indicator | IDAI | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 47.92 |
| Support Level | $4.00 | $1.85 |
| Resistance Level | $4.57 | $2.15 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 12.82 | 65.62 |
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.